Analysis of the Proteomic Market Market: Assessment of Market Size, Trends, Statistics, and Competitors
Global Proteomics Market by Product (Instruments, Reagents & Consumables, and Service), by Application (Drug Discovery, Clinical Diagnostics, and Others), by End Users (Hospitals & Clinical Laboratories, Pharmaceutical Companies, Academic Research Laboratories, and Other End Users), and by Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Market Size, Share, COVID-19 Impact, Regional Analysis & Forecast Till 2030
Category - Healthcare
Report Code - OMR-H-249
Format: PDF, PPT, and Excel
Proteomics Market Overview
Proteomics examines proteins and the biological processes in which they participate by analyzing their relationships, functions, compositions, and architectures. Understanding the structure and function of an organism using Proteomics is more in-depth than through genomics. Proteomics allows researchers to examine the quantitative and qualitative biological responses associated with a protein of interest by analyzing its expression at various levels. Proteomics is useful in many areas, including healthcare, cancer research, food safety, and agriculture. The key factor fueling this market's development is the number of studies conducted, notably in personalized medicine and medication discovery. Technology advancements, rising healthcare costs, increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for tailored medication, and rising prevalence of genetic illnesses are all expected to contribute to the industry's rapid growth worldwide over the next few years. One of the most encouraging results of research into human genes and proteins has been identifying possible new medications for treating illness. Yet, the market might be limited by variables, including the price of the instruments and stringent regulatory standards. COVID-19, a coronavirus, was spreading rapidly around the world, posing a serious threat to human health and the global economy. There was an immediate need for a deeper understanding of this infectious disease’s pathogenesis and the viral proteins' molecular functions. Several studies investigating the virus utilized Proteomics.
Proteomics Market Growth Factors
Rising Prevalence of Various Diseases to Propel Market Growth
The increasing incidence of chronic diseases such as cancer, cardiovascular diseases (CVDs), respiratory disorders, and others is also expected to fuel market expansion. By 2022, the American Cancer Society estimates that there will have been a little over 1.9 million new instances of cancer diagnosed in the United States. Worldwide, CVD was responsible for over 19.1 million deaths in 2020. For every 100,000 people, the death rate was 239.8 when adjusted for age. According to the American Heart Association, the adjusted prevalence rate was 7,354.1 cases per 100,000 people of all ages. As a result, with more people being diagnosed with potentially fatal illnesses, there is a growing need for individualized treatment plans, which is good news for the market.
Rising Investments to Augment Growth of the Market
The market is expected to rise during the forecast period due to increased expenditures by key players in developing innovative and effective pharmaceuticals and diagnostic instruments. In March 2022, the National Health Service (NHS) announced USD 290.5 million in March 2022 to support healthcare research. USD 223 million was allocated to fund NHS-led research in treatment and diagnostics, while USD 67 million was allocated to life sciences manufacturing in the UK. In January 2023, investment firm Novo Holdings, which operates globally, announced a USD 40 million investment in Evosep, the biotechnology business at the forefront of the movement to standardize Proteomics for clinical application. Moreover, in 2021, the members of the Pharmaceutical Research and Manufacturers of America spent nearly USD 102.3 billion on the research and development of new medicines. Ongoing funding and innovative medication development have occurred, drastically improving the health of individuals suffering from various illnesses and ailments, including chronic ones. Increased medicine demand may be expected due to these expenditures, which will spur pharmaceutical companies to speed up their research and depend more heavily on Proteomics services.
Proteomics Industry Segmentation
Product
• Instruments
o Spectrometry
o Protein Electrophoresis
o Microarray System
o Chromatography System
o Surface Plasmon Resonance
o Protein Fractionation Systems
o X-ray Crystallography
• Reagents & Consumables
• Services
Application
• Drug Discovery
• Clinical Diagnostics
• Others
End User
• Hospitals & Clinical Laboratories
• Pharmaceutical Companies
• Academic Research Laboratories
• Other End Users
Proteomics Market Regional Segmentation
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe (RoE)
Asia Pacific (APAC)
o Japan
o China
o India
o South Korea
o Rest of APAC
Latin America
o Argentina
o Brazil
o Rest of Latin America
Middle East & Africa
o South Africa
o UAE
o Saudi Arabia
o Rest of MEA
Product Insights
Reagents & Consumables are Dominant Owing to Increasing R&D Activities
Based on the product, the market can be differentiated between instruments, reagents & consumables, and services. The instruments segment is further categorized into spectrometry, protein electrophoresis, microarray, chromatography, surface plasmon resonance, protein fractionation, and x-ray crystallography.
The reagent & consumables segment held the majority share of the market. Demand for reagents & consumables, kits, chemicals, and strips will rise as more biological samples are analyzed at academic institutions, research labs, and other settings. The increased demand for new medications and the increasing frequency of product launches will likely contribute to the market expansion throughout the forecast period.
The instruments segment is expected to expand at a particularly rapid growth throughout the forecast period. As there is a growing market for automated diagnostic procedures and a low-cost platform for sample analysis, companies are taking a keener interest in developing new and improved instruments. The field of Proteomics has been at the forefront of recent developments in mass spectrometry (MS). For instance, the Max Planck Institute of Biochemistry, where the pioneering MS-based Proteomics data analysis and interpretation platform MaxQuant was updated by research group head Jürgen Cox and his team. MaxDIA, a new component of MaxQuant 2.0, is an enhanced computational approach for DIA Proteomics. Such developments are aiding the market growth to a certain extent.
Application Insights
Drug Discovery to Accommodate Largest Market Share Owing to Increasing Funding for Development of New Drugs
The market can be split based on the application between drug discovery, clinical diagnostics, and others.
The drug discovery segment is anticipated to hold the majority of the Proteomics market. One of the most exciting advances in studying human genes and proteins has been identifying possible new medications for treating illness. The data from the genome and proteome are utilized to pinpoint specific proteins linked to disease and can serve as medication targets. Virtually every major pharmaceutical firm has partnered with a biotech or academic institution specializing in Proteomics or has established an in-house Proteomics branch. In addition, Proteomics technologies provide a means to demonstrate early in a drug discovery effort, saving pharmaceutical companies substantial resources to the long-term advantage of patients and healthcare systems worldwide. Identifying effectiveness and toxicity indicators from easily accessible bodily fluids, target selection and validation, and studies into therapeutic action or toxicity mechanisms are only some of the general uses of Proteomics in the pharmaceutical sector.
The clinical diagnostics segment is expected to grow the fastest during the forecast period. Clinical researchers are increasingly turning to protein analysis to find disease biomarkers, which can be used for early diagnosis and pinpointing the specific causes of an illness. Due to this discovery, more options for preventing and treating the disease in its earliest stages will emerge. Proteomics-based diagnostics are useful in the classification and prediction of malignancies and in determining their prognosis, all of which contribute to the growth of this market.
Regional Insights
Asia Pacific to Lead Global Sales Owing to Extensive Infrastructure & High Traffic Congestion
Based on region, the market can be split between North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
The region of North America is expected to indicate significant dominance during the forecast period. Increased funding for structure-based drug design, increasing omics research, rising need for high-quality research tools for data reproducibility, and focus on developing individualized therapies all contribute to the market growth. Another factor aiding this industry's growth is the presence of major international companies in this region. More than a hundred different therapeutic proteins with modifications are now licensed in the region. There are now hundreds of protein therapies in clinical trials to treat cancer, immunological disorders, infections, age-related illnesses, and many other problems. In addition, countries like the United States have some of the world's most advanced Proteomics research facilities.
The highest projected CAGR throughout the forecasted period will come from Asia Pacific. This can be attributed to several factors, including expanding public and commercial financing for research and development in Proteomics, encouraging government laws, increasing target illnesses in an aging population, and the widespread usage of Proteomics.
In 2022, it is anticipated that the European market for proteomics will hold the second-largest market share. Proteomics technologies are increasingly utilized in drug discovery and development, clinical diagnostics, and personalized medicine, which drives the market. In the future years, it is anticipated that the European proteomics market will expand significantly.
Proteomics Industry Analysis
The market is moderately consolidated, with major players holding the largest market share. To strengthen their positions in the market, major firms are engaging in various tactics, such as mergers and acquisitions, regional growth, and strategic alliances. Proteomics is a rapidly evolving industry, and leading companies are rapidly adopting new technology.
Proteomics Market Recent Developments
• In January 2022, Seer, Inc. has announced the launch of its Centers of Excellence initiative and the general availability of its Proteograph Product Suite. Access to the proteome is unbiased and unparalleled with the Proteograph Product Suite. This method employs custom-made nanoparticles to generate a game-changing offering that paves the way for large-scale, rapid, comprehensive, and objective Proteomics.
Global Proteomics Market Prominent Players
• Agilent Technologies, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• GE HealthCare (U.S.)
• Merck KGaA (Germany)
• Danaher. (U.S.)
• Bruker (U.S.)
• Luminex Corporation. (U.S.)
Frequently Asked Questions (FAQs)
At what rate will the Proteomics Market Expand?
According to Objective Market Research, the global Proteomics Market will expand at a CAGR of 15.8% over the period of the forecast.
What are the factors driving the global Proteomics market?
The global Proteomics market is expected to grow during the forecast period owing to the increasing prevalence of various diseases, growing funding, and rising R&D activities.
Which segment accounted for the largest Proteomics market share by application?
Drug discovery is expected to dominate the largest market share during the forecast period due to growing research & development activities.
What region holds the major share in the global market scape?
North America will hold the largest share of the market owing to the rising investments in R&D activities for the development of novel medicines and the presence of major players.
Which are the dominating players in the market during the forecast period?
Some of the prominent players in the global Proteomics market are Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GE HealthCare (U.S.), Merck KGaA (Germany), Danaher. (U.S.), Bruker (U.S.), Luminex Corporation. (U.S.), among others.
*Our reports are available on a region/wise and chapter/wise basis as well. For any additional personalization contact our sales representative directly at sales@objectivemarketresearch.com
Table of Content
1. Introduction
1.1 Market Definition
1.2 Objective of the Study
1.3 Market Scope
1.4 Years Considered in the Study
1.4.1 Historic Year: 2019-2021
1.4.2 Base Year: 2022
1.4.3 Forecast Period: 2023-2030
1.5 Currency Used in the Study
1.6 Boundaries for the Study
1.7 Collaborators/Stakeholders/Benefactors
2. Research Methodology
2.1 Research Outline
2.2 Data Collection Methods
2.3 Data Sources
2.3.1 Secondary Sources
2.3.1.1 Paid Sources
2.3.1.2 Unpaid Sources
2.3.2 Primary Sources
2.4 Market Estimation Methodology
2.4.1 Top-Down Approach
2.4.2 Bottom-Up Approach
2.5 Data Triangulation
2.6 Assumptions of the Study
2.7 Limitations of the Study
3. Executive Summary
3.1 Market Outlook
3.2 Analysts Perspective
4. Market Overview
4.1 Market Dynamics
4.1.1 Drivers
4.1.1.1. Growing Prevalence of Cancer
4.1.1.2. Rising Research & Development Activities
4.1.2. Restrain
4.1.2.1. Higher Cost of the Instruments
4.1.3. Opportunities
4.1.3.1. Rising Private and Public Investments
4.1.4. Impact of Market Dynamics
4.2. Impact of COVID-19 pandemic
4.3. Value Chain Analysis
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitution
4.4.4. Threat of New Entrants
4.4.5. Competitive Rivalry
5. Global Proteomic Market Analysis & Forecast, by Product from 2019-2030 (in USD million)
5.1. Instruments
5.1.1. Spectrometry
5.1.2. Protein Electrophoresis
5.1.3. Microarray System
5.1.4. Chromatography System
5.1.5. Surface Plasmon Resonance
5.1.6. Protein Fractionation Systems
5.1.7. X-ray Crystallography
5.2. Reagents & Consumables
5.3. Services
6. Global Proteomic Market Analysis & Forecast, by Application from 2019-2030 (in USD million)
6.1. Drug Discovery
6.2. Clinical Diagnostics
6.3. Others
7. Global Proteomic Market Analysis & Forecast, by End User from 2019-2030 (in USD million)
7.1. Hospitals & Clinical Laboratories
7.2. Pharmaceutical Companies
7.3. Academic Research Laboratories
7.4. Other End Users
8. Global Proteomic Market Analysis & Forecast, by Region from 2019-2030 (in USD million)
8.1. North America
8.1.1. North America Halal Pharmaceuticals Market Analysis & Forecast, By Country
8.1.1.1. U.S.
8.1.1.2. Canada
8.1.1.3. Mexico
8.1.2. North America Proteomic Market Analysis & Forecast, By Product
8.1.3. North America Proteomic Market Analysis & Forecast, By Application
8.1.4. North America Proteomic Market Analysis & Forecast, By End User
8.2. Europe
8.2.1. Europe Proteomic Market Analysis & Forecast, By Country
8.2.1.1. Germany
8.2.1.2. UK
8.2.1.3. France
8.2.1.4. Spain
8.2.1.5. Italy
8.2.1.6. Rest of Europe (RoE)
8.2.2. Europe Proteomic Market Analysis & Forecast, By Product
8.2.3. Europe Proteomic Market Analysis & Forecast, By Application
8.2.4. Europe Proteomic Market Analysis & Forecast, By End User
8.3. Asia-Pacific (APAC)
8.3.1. Asia-Pacific Proteomic Market Analysis & Forecast, By Country
8.3.1.1. Japan
8.3.1.2. China
8.3.1.3. India
8.3.1.4. South Korea
8.3.1.5. Rest of the APAC
8.3.2. Asia-Pacific Proteomic Market Analysis & Forecast, By Product
8.3.3. Asia-Pacific Proteomic Market Analysis & Forecast, By Application
8.3.4. Asia-Pacific Proteomic Market Analysis & Forecast, By End User
8.4. Latin America
8.4.1. Latin America Proteomic Market Analysis & Forecast, By Country/Region
8.4.1.1. Argentina
8.4.1.2. Brazil
8.4.1.3. Rest of Latin America
8.4.2. Latin America Proteomic Market Analysis & Forecast, By Product
8.4.3. Latin America Proteomic Market Analysis & Forecast, By Application
8.4.4. Latin America Proteomic Market Analysis & Forecast, By End User
8.5. Middle East & Africa
8.5.1. Middle East & Africa Proteomic Market Analysis & Forecast, By Country/Region
8.5.1.1. South Africa
8.5.1.2. UAE
8.5.1.3. Saudi Arabia
8.5.1.4. Rest of Middle East & Africa
8.5.2. Middle East & Africa Proteomic Market Analysis & Forecast, By Product
8.5.3. Middle East & Africa Proteomic Market Analysis & Forecast, By Application
8.5.4. Middle East & Africa Proteomic Market Analysis & Forecast, By End User
9. Competitive Landscape
9.1. Market Share Analysis (2022)
9.2. Market Positioning of Top Players (2022)
9.3. Key Developments & Growth Strategies (2020-2022)
9.3.1. Product Launches
9.3.2. Merges, Collaborations & Agreements
9.3.3. Expansion
9.4. SWOT Analysis
10. Company Profiles (Business Overview, Products Offered, Financial Details*, Recent Developments)
10.1. Agilent Technologies, Inc. (U.S.)
10.1.1. Company Snapshot
10.1.2. Business Overview
10.1.3. Financial Data
10.1.4. Key Products Offered
10.1.5. Recent Developments
10.2. Illumina, Inc. (U.S.)
10.3. Bio-Rad Laboratories, Inc. (U.S.)
10.4. Thermo Fisher Scientific Inc. (U.S.)
10.5. F. Hoffmann-La Roche Ltd (Switzerland)
10.6. GE HealthCare (U.S.)
10.7. Merck KGaA (Germany)
10.8. Danaher. (U.S.)
10.9. Bruker (U.S.)
10.10. Luminex Corporation. (U.S.)
10.11. Others
11. Appendix
11.1. Currency Exchange Rate to USD
11.2. Abbreviations
* Financial details captured might be subjected to information available and not be given for privately-held companies or for companies that do not report it in the public domain